← Leaderboards
Andrew Sikora
Icahn School Of Medicine At Mount Sinai
$5,297,462
Attributed
$9,846,603
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2011–25$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,446,981 · 5
FDA$399,622 · 1
By mechanism
R01$5,019,430 · 3
U01$3,898,598 · 1
K08$674,325 · 1
R03$254,250 · 1
Top collaborators
- Ananth V Annapragada8 shared
- Jeffrey Nicholas Myers4 shared
- David John Tweardy4 shared
- Faye Johnson3 shared
Most similar at Icahn School Of Medicine At Mount Sinai
Same institution · by research overlap
- Samuel Sidi$6,036,228
- Barry S Rosenstein$1,165,913
- Hongdau Peter Liu$144,372
- Michael Schotsaert$3,271,645
- Sophia Siu$50,698
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseResistanceTumorDesignCellsHead And Neck CancerSmall MoleculeNovel StrategiesNeoplastic CellImmuneMouse ModelSolid NeoplasmImmunotherapyMediatingClinical TrialsMyeloid-Derived Suppressor CellsTumor ImmunityMalignant NeoplasmsRadiation TherapyChemotherapyImmune ResponseImmunosuppressionAnti-Pd1 TherapyIn Vitro
Grant awards (24)
Targeting head and neck cancer cells and the adverse tumor microenvironment with a novel small-molecule STAT3 inhibitor$666,718
R01 · FY2025 · CA
Functional roles of GOF TP53 mutations in metastasis and immunosuppression of head and neck cancers$556,146
R01 · FY2025 · DE
Functional roles of GOF TP53 mutations in metastasis and immunosuppression of head and neck cancers$545,024
R01 · FY2024 · DE
Targeting head and neck cancer cells and the adverse tumor microenvironment with a novel small-molecule STAT3 inhibitor$410,323
R01 · FY2024 · CA
Targeting head and neck cancer cells and the adverse tumor microenvironment with a novel small-molecule STAT3 inhibitor$657,573
R01 · FY2023 · CA
Functional roles of GOF TP53 mutations in metastasis and immunosuppression of head and neck cancers$556,146
R01 · FY2023 · DE
Targeting head and neck cancer cells and the adverse tumor microenvironment with a novel small-molecule STAT3 inhibitor$671,730
R01 · FY2022 · CA
Targeting the immunosuppressive tumor microenvironment to enhance efficacy of radiotherapy and immuno-radiotherapy for oral cancer$661,043
U01 · FY2022 · DE · contact PI
Functional roles of GOF TP53 mutations in metastasis and immunosuppression of head and neck cancers$556,148
R01 · FY2022 · DE
Targeting the immunosuppressive tumor microenvironment to enhance efficacy of radiotherapy and immuno-radiotherapy for oral cancer$64,165
U01 · FY2022 · DE · contact PI
Targeting the immunosuppressive tumor microenvironment to enhance efficacy of radiotherapy and immuno-radiotherapy for oral cancer$21,034
U01 · FY2022 · DE · contact PI
Targeting the immunosuppressive tumor microenvironment to enhance efficacy of radiotherapy and immuno-radiotherapy for oral cancer$745,334
U01 · FY2021 · DE · contact PI
Targeting the immunosuppressive tumor microenvironment to enhance efficacy of radiotherapy and immuno-radiotherapy for oral cancer$761,749
U01 · FY2020 · DE · contact PI
Targeting the immunosuppressive tumor microenvironment to enhance efficacy of radiotherapy and immuno-radiotherapy for oral cancer$776,961
U01 · FY2019 · DE · contact PI
Targeting the immunosuppressive tumor microenvironment to enhance efficacy of radiotherapy and immuno-radiotherapy for oral cancer$63,718
U01 · FY2019 · DE · contact PI
Targeting the immunosuppressive tumor microenvironment to enhance efficacy of radiotherapy and immuno-radiotherapy for oral cancer$804,594
U01 · FY2018 · DE · contact PI
Phase II trial of ADXS11-001 vaccine for HPV-related oropharyngeal cancer$399,622
R01 · FY2015 · FD · contact PI
TARGETING INOS TO INHIBIT MYELOID-DERIVED SUPPRESSOR CELLS (MDSC) IN MELANOMA$134,865
K08 · FY2015 · CA · contact PI
TARGETING INOS TO INHIBIT MYELOID-DERIVED SUPPRESSOR CELLS (MDSC) IN MELANOMA$134,865
K08 · FY2014 · CA · contact PI
Targeting iNOS to inhibit myeloid-derived suppressor cells (MDSC) in melanoma$134,865
K08 · FY2013 · CA · contact PI
Targeting iNOS to inhibit myeloid-derived suppressor cells (MDSC) in melanoma$134,865
K08 · FY2012 · CA · contact PI
Role of Activated EGFR and COX-2 in Metastasis and Escape from Tumor Dormancy$127,125
R03 · FY2012 · DE · contact PI
Targeting iNOS to inhibit myeloid-derived suppressor cells (MDSC) in melanoma$134,865
K08 · FY2011 · CA · contact PI
Role of Activated EGFR and COX-2 in Metastasis and Escape from Tumor Dormancy$127,125
R03 · FY2011 · DE · contact PI